title: Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide.
abstract: The influence of tumor temperature (28, 32, 37, 39, 41, or 43 degrees C for 1 h) on the therapeutic efficacy of i.v. single bolus injections of ifosfamide (IFO) (32, 65, 125, or 250 mg/kg body weight) in human tumor xenografts (MX1 breast carcinoma) grown in nude mice (n = 240) was studied. Tumor temperature was controlled by water bath immersion. Sixty days after treatment the percentage of tumor-free survival was determined. For example, at 37 degrees C IFO in a dose of 65 mg/kg body weight led to 10% tumor-free survival in the treated animals. At 43 degrees C the same dose resulted in 60% tumor-free survival. A clear drug dose- and temperature-dependent increase of the therapeutic efficacy of an active oxazaphosphorine compound was also demonstrated in vitro. The concentrations of IFO and of 4-hydroxyifosfamide in blood and tumors at different body temperatures (controlled by water bath immersion) were determined over 120 min and WBC counts were obtained. The half-lives and the areas under the curve for IFO in blood were not significantly different at 37 degrees C and 41 degrees C. Since the half-life of IFO depends mainly on hepatic metabolism, the similarity of half-lives and of areas under the curve for IFO at 37 degrees C and 41 degrees C indicates a constant activation rate. However, significantly lower plasma concentrations of the activated drug at a liver (body) temperature of 41 degrees C, compared with 37 degrees C, were found, indicating a higher elimination rate. The concentration of the activated drug in the tumors within the initial 60 min at 41 degrees C, however, exceeded by > 2-fold that at 37 degrees C. The bone marrow toxicity of the same drug dose did not significantly increase with body temperature.
authors.affiliation: Department of Internal Medicine, Medical University of Lübeck, Germany.
authors.forename: G J
authors.initials: GJ
authors.lastname: Wiedemann
authors.forename: H J
authors.initials: HJ
authors.lastname: Siemens
authors.forename: M
authors.initials: M
authors.lastname: Mentzel
authors.forename: A
authors.initials: A
authors.lastname: Biersack
authors.forename: W
authors.initials: W
authors.lastname: Wössmann
authors.forename: D
authors.initials: D
authors.lastname: Knocks
authors.forename: C
authors.initials: C
authors.lastname: Weiss
authors.forename: T
authors.initials: T
authors.lastname: Wagner
mesh_terms: D000818:Animals; D001831:Body Temperature; D001943:Breast Neoplasms; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D007069:Ifosfamide